ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
41 announcements
Windlass Biotech reports Mr. Ashok Kumar Windlass ceased as Executive Director, resigning for succession planning, effective 5 November 2026. He moves to Founder President, and Hitesh Windlass becomes Managing Director.
Windlas Biotech reported H1 FY27 revenue of Rs 512 crore, up 18% YoY. Adjusted PAT rose 33% to Rs 50 crore for the half year.
H1FY27 revenue Rs 512 Cr (+18%), adj. PAT Rs 50 Cr (+33%, 9.7% margin); reported PAT flat at Rs 36 Cr on ESOP charges. CDMO-led growth; Plant-6 commercialised.
Windlas Biotech Ltd reported revenue from operations of ₹263.9 Cr (+18.7% YoY) and net profit of ₹18.1 Cr (+1.7% YoY) for Q2 FY27.
Windlas Biotech disclosed a cyber security incident on 30 October 2026. It states no material impact on core operations, finances or business continuity.
Windlas Biotech intimated that its Board meeting is scheduled for 5 November 2026 to consider unaudited standalone results for Q1 FY27. No monetary figure is disclosed in this advance notice.
This quarterly shareholding pattern statement for Windlas Biotech Ltd, covering the period ended September 30, 2026, provides the company's equity ownership breakdown.
Windlas Biotech appointed Aashish Mehra and Soni Saran Singh as Independent Directors. Vivek Dhariwal resigned as Independent Director and Chairman of the Board.
Windlas Biotech reported record quarterly revenue driven by 29% growth in CDMO vertical. Management focuses on operational excellence and capacity expansion via Plant 6 commercialization.
Windlas Biotech reported Q1 FY27 revenue of Rs 248 crore, an 18% YoY growth. The release highlights an adjusted EBITDA of Rs 34 crore and PAT of Rs 25 crore.
Windlas Biotech reported Q1FY27 revenue of ₹248 Cr (18% YoY). Adjusted EBITDA and PAT grew 26% and 37% respectively, excluding ESOP costs, driven by CDMO expansion.
Windlas Biotech Ltd reported revenue from operations of ₹248.1 Cr (+18.1% YoY) and net profit of ₹17.7 Cr (+0.0% YoY) for Q1 FY27.
Windlas Biotech Limited has scheduled a board meeting on August 10, 2026, to consider and approve its unaudited standalone financial results for the quarter ending June 30, 2026.
Windlas Biotech Ltd held its 25th Annual General Meeting on July 23, 2026. Shareholders approved the financial statements and a final dividend of Rs. 6.30 per share.
Windlas Biotech Limited filed its Annual Report for the financial year 2025-26. The report highlights the company's operational performance and growth milestones.
Windlas Biotech Ltd announced a dividend of Rs.6.30 per share (126% of face value) for FY 2025-26. Record date is set for July 16, 2026.
ICRA reaffirmed Windlas Biotech's long-term rating at [ICRA]A+(Stable) and upgraded short-term facilities to [ICRA]A1+. The rated amount totals ₹84.9 Crore.
Windlas Biotech reported record FY26 revenue of ₹904cr (up 19% YoY) and highest post-listing EPS of ₹31.60. Management emphasized scalability, capital efficiency (ROCE/ROE >25%), and diversification into injectables and exports.
Windlas Biotech submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report confirms regulatory compliance with no material deviations noted.
Windlas Biotech granted 37,000 stock options and units under its ESOP 2023 and Plan 2025 schemes. The grants aim to incentivize and retain eligible employees.
Windlas Biotech recommended a final dividend of ₹6.3 per equity share for the fiscal period. This payout reflects the company's commitment to returning capital to shareholders.
Windlas Biotech reported record FY26 revenue of ₹904 Crore, representing 19% year-on-year growth. Adjusted PAT rose 31% to ₹83 Crore, reflecting strong operational performance.
Windlas Biotech reported record annual revenue of ₹904 Cr in FY26, a 19% YoY growth, driven by its CDMO vertical. The company maintained a strong net liquidity position of ₹251 Cr with zero net debt.
Windlas Biotech Ltd reported revenue from operations of ₹238.5 Cr (+17.7% YoY) and net profit of ₹16 Cr (-1.8% YoY) for Q4 FY26.
Windlas Biotech approved audited FY26 financial results and recommended a Rs. 6.30 per share dividend. The company reported unmodified audit opinions for both standalone and consolidated statements.
Windlas Biotech reported temporary production disruptions due to statewide labour unrest in Uttarakhand. Operations resumed quickly with management expecting no material impact on financial performance.
Windlas Biotech extinguished 4,70,000 shares following a ₹47 Crore buyback at ₹1,000 per share. The move reduces equity capital and enhances shareholder value.
Windlas Biotech Limited completed a ₹47 Crore share buyback via tender offer. The company repurchased 4,70,000 equity shares, reducing its total paid-up share capital.
Windlas Biotech Limited appointed Dr. Tarashree Singhal as a Non-Executive Independent Director for a five-year term effective May 5, 2026. Simultaneously, Mr. Srinivasan Venkataraman concluded his tenure as an Independent Director on May 6, 2026. These leadership changes were approved during the board meeting held on May 5, 2026.
Windlas Biotech Limited appointed Dr. Tarashree Singhal as an Independent Woman Director for five years effective May 5, 2026. Simultaneously, Mr. Srinivasan Venkataraman ceased to be a director after completing his five-year term. These changes ensure board continuity and compliance with independent director regulations.